Alamar Biosciences: Revolutionizing Precision Proteomics
February 28, 2024, 9:15 am
Location: United States, California, Fremont
Employees: 11-50
Founded date: 2018
Total raised: $128M
Alamar Biosciences, a Fremont-based company, recently secured $128M in Series C funding to advance their innovative precision proteomics platform. Led by Sands Capital, this funding round will propel the company's mission to enable early disease detection through cutting-edge technology.
Alamar Biosciences, under the leadership of Dr. Yuling Luo, is on a mission to transform the landscape of disease detection. With their NULISA technology, they offer unmatched sensitivity, precision, and efficiency in protein biomarker analysis. This technology, with a 10,000-fold improvement in signal-to-noise ratio, allows for the detection of proteins at incredibly low concentrations, revolutionizing the way diseases are diagnosed.
The recent funding will be utilized to expand the company's commercial and customer support teams, drive market adoption, and enhance their product line. With the ARGO HT System and the NULISAseq Inflammation Panel 250, Alamar Biosciences is at the forefront of precision proteomics, providing researchers and clinicians with the tools they need to accelerate biomarker discovery and develop non-invasive tests for diseases with high unmet needs.
Dr. Yuling Luo expressed gratitude for the overwhelming support from investors, highlighting the company's game-changing technology, solid IP, and early market adoption. With this funding, Alamar Biosciences is well-positioned to lead the way in precision proteomics and transform the future of disease detection.
Alamar Biosciences, under the leadership of Dr. Yuling Luo, is on a mission to transform the landscape of disease detection. With their NULISA technology, they offer unmatched sensitivity, precision, and efficiency in protein biomarker analysis. This technology, with a 10,000-fold improvement in signal-to-noise ratio, allows for the detection of proteins at incredibly low concentrations, revolutionizing the way diseases are diagnosed.
The recent funding will be utilized to expand the company's commercial and customer support teams, drive market adoption, and enhance their product line. With the ARGO HT System and the NULISAseq Inflammation Panel 250, Alamar Biosciences is at the forefront of precision proteomics, providing researchers and clinicians with the tools they need to accelerate biomarker discovery and develop non-invasive tests for diseases with high unmet needs.
Dr. Yuling Luo expressed gratitude for the overwhelming support from investors, highlighting the company's game-changing technology, solid IP, and early market adoption. With this funding, Alamar Biosciences is well-positioned to lead the way in precision proteomics and transform the future of disease detection.